ストックスクリーナーアプリを入手
53.48
2.96%
1.54
アフターアワーズ：
53.48
前日終値:
$51.94
開ける：
$51.87
24時間の取引高:
1.45M
Relative Volume:
0.57
時価総額：
$10.22B
収益：
$217.77M
当期純損益:
$-438.86M
株価収益率:
-22.19
EPS:
-2.41
ネットキャッシュフロー:
$-456.33M
1週間 パフォーマンス:
+5.59%
1か月 パフォーマンス:
+3.32%
6か月 パフォーマンス:
+61.96%
1年 パフォーマンス:
+115.65%
1日の値動き範囲:
$51.87
$53.81
1週間の範囲:
$48.78
$53.81
52週間の値動き範囲:
$21.72
$54.60
Bridgebio Pharma Inc Stock (BBIO) Company Profile
BBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
53.48 | 9.93B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
404.21 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.94 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.65 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
767.33 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
335.16 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-14 | 開始されました | Jefferies | Buy |
| 2025-07-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-03 | 開始されました | Oppenheimer | Perform |
| 2024-09-04 | 開始されました | Piper Sandler | Overweight |
| 2024-03-21 | 再開されました | Raymond James | Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-07 | 開始されました | Citigroup | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-19 | 開始されました | Evercore ISI | Outperform |
| 2023-02-06 | 開始されました | Cowen | Outperform |
| 2021-12-27 | 繰り返されました | Mizuho | Buy |
| 2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
| 2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-03-22 | 繰り返されました | Goldman | Buy |
| 2021-02-22 | 再開されました | JP Morgan | Overweight |
| 2021-02-09 | 再開されました | Goldman | Buy |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Neutral |
| 2020-05-19 | 開始されました | BTIG Research | Buy |
| 2020-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-19 | 開始されました | Mizuho | Buy |
| 2019-07-26 | 開始されました | Raymond James | Outperform |
| 2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
| 2019-07-22 | 開始されました | Goldman | Buy |
| 2019-07-22 | 開始されました | JP Morgan | Overweight |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-07-22 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
Hypoparathyroidism Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart.com
Pattern recognition hints at BridgeBio Pharma Inc. upsideForecast Cut & Long Hold Capital Preservation Tips - newser.com
How big funds are accumulating BridgeBio Pharma Inc. (2CL) stockDollar Strength & Consistent Return Investment Signals - newser.com
Real time breakdown of BridgeBio Pharma Inc. stock performanceJuly 2025 Momentum & Short-Term High Return Strategies - newser.com
Why BridgeBio Pharma Inc. (2CL) stock could outperform next yearJuly 2025 Update & Expert Curated Trade Ideas - newser.com
Analyzing drawdowns of BridgeBio Pharma Inc. with statistical toolsTrade Volume Report & Reliable Intraday Trade Alerts - newser.com
What earnings revisions data tells us about BridgeBio Pharma Inc.2025 Market Overview & Weekly Market Pulse Updates - newser.com
How buybacks impact BridgeBio Pharma Inc. stock valueWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
Is BridgeBio Pharma Inc a good long term investmentMarket Sentiment Surveys & Access Free Tools and Start Investing - earlytimes.in
What MACD and RSI say about BridgeBio Pharma Inc.Trade Entry Report & Verified Swing Trading Watchlist - newser.com
BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition - Yahoo
Moss Adams Wealth Advisors LLC Has $1.04 Million Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: A Biotech Powerhouse with a 32.50% Potential Upside - DirectorsTalk Interviews
BridgeBio Pharma Says Drug Reduced Death, Hospitalization in Cardiomyopathy Patients After 1 Month - MarketScreener
Will breakout in BridgeBio Pharma Inc. lead to full recovery2025 Market WrapUp & Stepwise Trade Signal Guides - newser.com
What analysts say about BridgeBio Pharma Inc stockEarnings Beat Highlights & Small Budget Investment Tips - earlytimes.in
BridgeBio (BBIO) Unveils Positive Results in ATTRibute-CM Study - GuruFocus
BridgeBio Pharma says Acoramidis reduces CVM or CVH risk by 49% through month 30 - MarketScreener
BridgeBio Pharma Reports Positive Results from ATTRibute-CM Study, Demonstrating Significant Reduction in Cardiovascular Outcomes with Acoramidis - Quiver Quantitative
53 Heart Events Prevented Per 100 Patients: BridgeBio's Acoramidis Shows Powerful Early Benefits in ATTR-CM - Stock Titan
What technical models suggest about BridgeBio Pharma Inc.’s comebackJuly 2025 Review & Consistent Income Trade Ideas - newser.com
BridgeBio Pharma Inc Stock Analysis and ForecastPortfolio Allocation Tips & Smart Beta Strategies That Actually Work - earlytimes.in
Best data tools to analyze BridgeBio Pharma Inc. stockStop Loss & Stepwise Swing Trade Plans - newser.com
H.C. Wainwright Reiterates a Buy on BridgeBio Pharma (BBIO) - MSN
Retirement Income Solutions Inc Acquires Shares of 5,000 BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma’s Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism - Yahoo Finance
Atle Fund Management AB Grows Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Assenagon Asset Management S.A. Has $15.13 Million Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Strs Ohio Makes New Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio to Present Additional Cardiovascular Outcomes - GlobeNewswire
BridgeBio Pharma to Present Key Clinical Trial Findings at Heart Failure Society of America Annual Scientific Meeting 2025 - Quiver Quantitative
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 - The Manila Times
New Cardiovascular Outcomes Data: BridgeBio's Acoramidis Shows Impact on ATTR-CM Patient Survival - Stock Titan
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a Biotech Powerhouse with 24% Upside Potential - DirectorsTalk Interviews
Risks To Shareholder Returns Are Elevated At These Prices For BridgeBio Pharma, Inc. (NASDAQ:BBIO) - 富途牛牛
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. $BBIO Stock Position Lifted by Intech Investment Management LLC - MarketBeat
Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT - MSN
Fed Watch: Should value investors consider BridgeBio Pharma IncQuarterly Trade Report & Capital Efficient Trading Techniques - خودرو بانک
BridgeBio Pharma (NASDAQ:BBIO) Earns Buy Rating from HC Wainwright - MarketBeat
Aug Mood: What is the Moat Score of BridgeBio Pharma IncWeekly Trade Analysis & Weekly Watchlist for Hot Stocks - خودرو بانک
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
2.95%
1.63%
大文字化:
|
ボリューム (24 時間):